In 2024, Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound generated $8 billion and $4.9 billion, respectively. So, this is approximately a $15 billion market ... loss is its impact on meaningful ...

Lilly announced the results on Wednesday, claiming that Zepbound outperforms Wegovy, which has been a leader in the weight loss market ... trial that examined the impact of both drugs on patients ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide ... chiefly that it was not a blinded analysis and participants knew which medication they ...

Eli Lilly will add 12.5 mg and 15 mg single-dose vials of its weight loss drug Zepbound to its LillyDirect platform starting July 7, completing the full range of approved doses. All vial doses, ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA asset tirzepatide, respectively sold under the brand names Zepbound and ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...